Aggregate-selective antibody attenuates seeded aggregation but not spontaneously evolving disease in SOD1 ALS model mice

Table 1 Disease and survival data of seed inoculated hSOD1^G85R Tg mice receiving systemic administration of mAbs

	No mAb control		αSOD1^65–72 (10 mg/kg)		αSOD1^65–72 (50 mg/kg)		αSOD1^143–153 (10 mg/kg)		αSOD1^143–153 (50 mg/kg)		pAb IgG (50 mg/kg)
	n	days	n	days	n	days	n	days	n	days	n	days
Age at 1st mAb injection	–	–	5	76 ± 2	5	76 ± 2	5	79	9	79 ± 3	9	78 ± 3
Age at SOD1^G85R seed inoculation	9	100 ± 4	5	98 ± 2	5	99 ± 2	5	101 ± 1	9	101 ± 3	9	100 ± 3
Paralytic end-stage (days post-inoculation)	9	94 ± 14	5	88 ± 24	5	78 ± 2	5	118 ± 35	9	185 ± 101	9	113 ± 59
Symptom onset (days post-inoculation)	6	69 ± 13	5	73 ± 17	5	62 ± 5	5	100 ± 25	9	175 ± 102	9	101 ± 63
Age at paralytic end-stage	9	195 ± 13	5	187 ± 26	5	177 ± 3**	5	219 ± 35	9	286 ± 100*^,	9	214 ± 58

ISSN: 2051-5960